With the prolongation of life, immune thrombocytopenia (ITP) is becoming more and more frequent in the elderly. At present,the research object of ITP is mainly aimed at children and adults,and there is less research on the elderly. The therapeutic strategy differs from that for younger patients and must consider the greater risk of bleeding and thrombosis,poor life expectancy and concomitant medications. This review summarizes the current status of treatment for elderly patients with ITP.